SCHEMBL29944255

SCHEMBL29944255

Cc1nc(C(=O)N2CCCCC2)cs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
ALDH1A1 P00352 3/20 0.57
PKM P14618 1/20 0.57
HTR2C P28335 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
GFER P55789 1/20 0.52
HPGD P15428 4/20 0.51
MAPK1 P28482 1/20 0.51
HRH3 Q9Y5N1 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TRPC3 Q13507 1/20 0.47
TRPC6 Q9Y210 1/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26707398 0.84 HPGD (0.61) NPC1RAB9AHTR2CHPGDHRH3
SCHEMBL16207649 0.84 NPC1 (0.45) NPC1RAB9AALDH1A1PKMHTR2C
SCHEMBL16132298 0.80 HTR2C (0.44) NPC1RAB9AALDH1A1PKMHTR2C
SCHEMBL26702878 0.80 KMT2A (0.54) NPC1RAB9AALDH1A1HTR2CMEN1
SCHEMBL11743656 0.80 ALDH1A1 (0.44) NPC1RAB9AALDH1A1PKMHTR2C
SCHEMBL18131017 0.79 HTR2C (0.51) NPC1RAB9AALDH1A1HTR2CMEN1
SCHEMBL23573227 0.78 GFER (0.51) NPC1RAB9AALDH1A1PKMHTR2C
SCHEMBL3540590 0.78 ALDH1A1 (0.61) NPC1RAB9AALDH1A1PKMHTR2C
SCHEMBL11744272 0.78 ALDH1A1 (0.45) NPC1RAB9AALDH1A1PKMGFER
SCHEMBL18781654 0.77 MEN1 (0.59) NPC1RAB9AALDH1A1PKMHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230110003-A1 PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) Valo Health, LLC 2023-04-13 US disclosed
US-11479564-B2 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) VALO HEALTH, INC. (US) 2022-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230110003-A1 PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) NAMPT, NAPRT, NNMT NPC1 322/4885RAB9A 2108/4885ALDH1A1 265/4885
US-11479564-B2 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) NAMPT, NAPRT, NNMT NPC1 322/4885RAB9A 2108/4885ALDH1A1 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.